Mimedx (MDXG) Free Cash Flow (2011 - 2026)
Mimedx (MDXG) posted Free Cash Flow of -$10.6 million for Q2 2026, down 910.77% sequentially from $1.3 million in Q1 2026, and down 174.53% YoY from $14.2 million in Q2 2025.
Mimedx (MDXG) Free Cash Flow (2011 - 2026) Analysis & Trends
Mimedx has reported Free Cash Flow for 16 years, with the latest figure at -$10.6 million in Q2 2026.
- Quarterly Free Cash Flow fell 174.53% year-over-year to -$10.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $44.5 million (down 22.11% YoY) and the FY2025 annual result came in at $73.0 million, up 11.5% from the prior year.
- Free Cash Flow slipped to -$10.6 million in Q2 2026 per MDXG's latest filing, from $1.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $29.1 million in Q3 2025 and troughed at -$10.6 million in Q2 2026.
- A 5-year average of $7.9 million and a median of $7.2 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 383.5% in 2022, then jumped 1944.59% in 2023.
- Over 5 years, Free Cash Flow stood at -$6.3 million in 2022, then soared by 240.57% to $8.8 million in 2023, then soared by 109.41% to $18.5 million in 2024, then soared by 33.23% to $24.7 million in 2025, then slumped by 143.02% to -$10.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$10.6 million, $1.3 million, and $24.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | -10.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.61 Mn |
| Jun 30, 2026 | -10.61 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | 24.67 Mn |
| Dec 31, 2025 | 24.67 Mn |
| Sep 30, 2025 | 29.14 Mn |
| Sep 30, 2025 | 29.14 Mn |
| Jun 30, 2025 | 14.24 Mn |
| Jun 30, 2025 | 14.24 Mn |
| Mar 31, 2025 | 4.92 Mn |
| Mar 31, 2025 | 4.92 Mn |
| Dec 31, 2024 | 18.52 Mn |
| Dec 31, 2024 | 18.52 Mn |
| Sep 30, 2024 | 19.45 Mn |
| Sep 30, 2024 | 19.45 Mn |
| Jun 30, 2024 | 21.83 Mn |
| Jun 30, 2024 | 21.83 Mn |
| Mar 31, 2024 | 5.64 Mn |
| Mar 31, 2024 | 5.64 Mn |